| abstract |
Disclosed are 7-alkyl-6,6a,7,8,9,10,10a,11-octahydro-1,3-dioxa-7-azacyclopenta[a]anthracene derivatives as represented by the general formula I, wherein n is 0 or 1; R1 and R2 are fused and form a methylene (CH2) group, a carbonyl (C=O) group, or an oxalyl (O=C-C=O) group; R3 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, cyclopropyl, cyclobutyl, allyl, propargyl, hydroxyethyl, 3-fluoropropyl and 2-fluoroethyl. Further disclosed is a pharmaceutical composition which comprises a therapeutically effective amount of a compound as defined above, and one or more pharmaceutically acceptable carriers, diluents and excipients, and pharmaceutically acceptable acid addition salts thereof for the treatment of neurological disorders such as Parkinson's disease, Huntington's disease, schizophrenia, dementia, depression and Alzheimer's disease. . |